



TREATMENT OPTIONS FOR BREAST CANCER

AWARENESS OF THE DEVELOPMENT OF BISPECIFIC ANTIBODIES IN THE TREATMENT OF BREAST CANCER




While bispecific antibodies are on the radar for most clinicians, very few feel deeply familiar — revealing a clear opportunity for targeted education to support future integration into breast cancer treatment strategies.

ACCESS TO BISPECIFIC ANTIBODY CLINICAL TRIALS IN BREAST CANCER




Most clinicians report either no access or uncertainty about access to bispecific antibody trials, indicating that trial availability is still limited or not established across many practices.

EXPECTED IMPACT OF BISPECIFIC ANTIBODIES ON THE BREAST CANCER TREATMENT LANDSCAPE: COMMUNITY ONCOLOGIST PERSPECTIVES



Clinicians are broadly optimistic about the role of bispecific antibodies in breast cancer, with most anticipating meaningful change, though relatively few view their impact as significant at this stage.

BARRIERS TO EXPANDING USE OF BISPECIFIC ANTIBODIES IN BREAST CANCER



Clinicians identify all listed factors as meaningful barriers to expanding bispecific antibody use in breast cancer, with toxicity concerns and limited data ranking highest, but cost and patient selection are also viewed as relevant challenges.